Elevance (ELV) Q3 2026 Earnings Call Transcript

Elevance reported Q3 adjusted diluted EPS of $6.99, above its outlook, and raised 2026 adjusted EPS guidance to at least $29; its 2026 earnings baseline rose $0.75 to at least $26.75. Revenue increased 0.7% to $50.4 billion, while the benefit expense ratio improved 70 basis points to 90.6%; management expects at least 12% adjusted EPS growth in 2027. Medicaid rate actions and Carelon performance supported results, but management cautioned that Medicaid rates have not fully caught up with costs and cited excessive awards and process disputes in the IDR system as cost pressures.

Analysis

The quality of the beat matters more than the $29 EPS headline: management attributes $1.85/share to non-operating items, while its $26.75 baseline is the cleaner underwriting anchor. The operating case is improving, but the 2027 growth promise still depends on Medicaid rates catching up with persistently elevated costs and on execution translating Carelon’s clinical claims into durable earnings. That leaves ELV exposed to a two-sided reset: investors may discount the guide if they focus on the non-operating uplift, or re-rate it if the higher baseline proves sustainable.

The main downside asymmetry is Medicaid. Rate updates improve the near-term run rate, but states’ assumptions, work-requirement implementation, and resulting member acuity remain uncertain; adverse acuity could absorb rate gains. IDR pressure is also uneven: management says its exposure is more pronounced in ASO, where employer clients ultimately bear claims costs. That can pressure affordability and retention even if ELV’s own pricing is disciplined. Higher claims-payable days warrant monitoring alongside cash flow; the change alone does not establish reserve release or deterioration.

Carelon offers a potential buffer through services and pharmacy integration, but reported growth is not yet proof of scalable external economics. Track external wins and retention separately from internal adoption, and verify whether savings claims convert into margin and cash. Over 1–3 months, January’s 2027 assumptions and state-rate visibility are key catalysts; over 6–18 months, Medicaid margin recovery and Carelon scaling determine whether multiple expansion is justified. The contrarian point: a strong quarter does not remove the earnings-quality discount, but treating all improvement as temporary may also understate the cleaner baseline.

Key Decisions for Investors

• Do not chase the headline EPS beat. Consider a measured ELV long only on post-results weakness if the cleaner $26.75 baseline remains credible; size against the risk that Medicaid recovery slips. Reassess at January guidance, with a thesis break if management withdraws the 2027 growth outlook or signals rates lagging cost trends.
• Treat Medicaid as the key 1–3 month monitoring item: track state 2027 rate filings, work-requirement implementation, enrollment and acuity commentary. Better rates without margin improvement would falsify the recovery thesis.
• Monitor Carelon for evidence of external monetization—not just internal integration—including contract wins, retention, segment operating gains and cash conversion. If these fail to scale, avoid paying for Carelon as a material growth premium.
• Track claims-payable days and operating cash flow together in subsequent quarters. A sustained rise in payable days without commensurate underlying cash generation would weaken confidence in earnings quality.